LEXICON PHARMACEUTICALS, INC.

Inactive Instrument

Analyst Reco. Lexicon Pharmaceuticals, Inc. Nasdaq

Equities

US5288721047

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Lexicon Pharmaceuticals Files Prospectus for Secondary Offering	Mar. 25	MT
North American Morning Briefing: Treasury Yields Dive as Rate-Rise Fears Ease	23-10-10	DJ
Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $8 From $6, Keeps Buy Rating	23-05-31	MT
Jefferies Starts Lexicon Pharmaceuticals at Hold With $3 Price Target	23-03-07	MT
Lexicon Pharmaceuticals Shares Rise After Piper Sandler Initiates Coverage	22-08-12	MT
Piper Sandler Starts Lexicon Pharmaceuticals at Overweight With $10 Price Target	22-08-12	MT
Citigroup Adjusts Lexicon Pharmaceuticals' Price Target to $20 from $18, Keeps Buy Rating	22-07-01	MT
LEXICON PHARMACEUTICALS : Wedbush Suspended Coverage on Lexicon Pharmaceuticals	21-10-11	MT
LEXICON PHARMACEUTICALS : Citigroup Adjusts Price Target on Lexicon Pharmaceuticals to $20 From $13, Maintains Buy Rating	21-08-30	MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals' PT to $5 From $8 on Adjusted Timelines for Sotaglifozin/Heart Failure, Xermelo/BTC; Neutral Rating Kept	21-05-11	MT
LEXICON PHARMACEUTICALS : JPMorgan Upgrades Lexicon Pharmaceuticals to Neutral From Underweight; Price Target is $7	21-01-29	MT
LEXICON PHARMACEUTICALS : Wedbush Cuts Lexicon Pharmaceuticals to Neutral From Outperform Pending Clarity on Sotagliflozin Partnership; PT to $8 From $2	21-01-29	MT
LEXICON PHARMACEUTICALS : Citigroup Upgrades Lexicon Pharmaceuticals to Buy From Neutral, Adjusts Price Target to $6 From $2.10	20-12-08	MT
LEXICON PHARMACEUTICALS : Gabelli Upgrades Lexicon Pharmaceuticals to Buy From Hold	20-11-18	MT
LEXICON PHARMACEUTICALS : Wedbush Adjusts Price Target on Lexicon Pharmaceuticals to $2 From $3, Keeps Outperform Rating	20-11-03	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Discover our Free Content to Help You Better Understand the Stock Market.

100% Free Registration

fermer